Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen G Mainz

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Frontiers in Pharmacology|November 29, 2023
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaireJochen G Mainz, Anton Barucha, Pu Huang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 11, 2013
Therapy of CF-patients with amitriptyline and placebo--a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-studyLutz Nährlich, Jochen G Mainz, Constantin Adams, et al.
European Radiology|October 20, 2021
Ultrashort echo time MRI of the lung in children and adolescents: comparison with non-enhanced computed tomography and standard post-contrast T1w MRI sequencesDiane M Renz, Karl-Heinz Herrmann, Martin Kraemer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 6, 2024
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)Alexander Yule, Christabella Ng, Arantxa Recto, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 3, 2024
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosisMichael Wilschanski, Anne Munck, Estefania Carrion, et al.
The Journal of Clinical Investigation|January 26, 2023
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosisCarsten Schwarz, Patience Eschenhagen, Henrijette Schmidt, et al.
Plos One|November 19, 2016
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureusSibylle Junge, Dennis Görlich, Martijn den Reijer, et al.
Pneumologie (Stuttgart, Germany)|February 13, 2024
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]Carsten Schwarz, Jutta Bend, Helge Hebestreit, et al.
Pneumologie (Stuttgart, Germany)|February 29, 2024
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]Carsten Schwarz, Jutta Bend, Helge Hebestreit, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Frontiers in Pharmacology|November 29, 2023
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaireJochen G Mainz, Anton Barucha, Pu Huang, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 11, 2013
Therapy of CF-patients with amitriptyline and placebo--a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-studyLutz Nährlich, Jochen G Mainz, Constantin Adams, et al.
European Radiology|October 20, 2021
Ultrashort echo time MRI of the lung in children and adolescents: comparison with non-enhanced computed tomography and standard post-contrast T1w MRI sequencesDiane M Renz, Karl-Heinz Herrmann, Martin Kraemer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 6, 2024
A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI)Alexander Yule, Christabella Ng, Arantxa Recto, et al.
Clinical Nutrition (Edinburgh, Scotland)|January 3, 2024
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosisMichael Wilschanski, Anne Munck, Estefania Carrion, et al.
The Journal of Clinical Investigation|January 26, 2023
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosisCarsten Schwarz, Patience Eschenhagen, Henrijette Schmidt, et al.
Plos One|November 19, 2016
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureusSibylle Junge, Dennis Görlich, Martijn den Reijer, et al.
Pneumologie (Stuttgart, Germany)|February 13, 2024
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]Carsten Schwarz, Jutta Bend, Helge Hebestreit, et al.
Pneumologie (Stuttgart, Germany)|February 29, 2024
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]Carsten Schwarz, Jutta Bend, Helge Hebestreit, et al.
Pageof 8